Statin and SGLT2i

PreclinicalSmall molecule

FFayoum University

Statin and SGLT2i is one of 43 small molecule programs targeting Heart Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart DiseaseActive, not recruiting

Heart DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

166 competitors in Heart Disease

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

9 2

Ozempic

Novo Nordisk

Phase 3

1 3

Biaxin

AbbVie

Phase 3

1 4

Aldactone

Pfizer

Phase 3

1 5

Lopid

Pfizer

Phase 3

1 6

Depo-Provera

Activella

Zoloft

VViatris Specialty LLC

Phase 3

2 9

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

1 10

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Disease1 trial

"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

Recruiting·FFayoum University··NCT06520891·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Statin and SGLT2i. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Statin and SGLT2i compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Statin and SGLT2i. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fayoum University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFayoum University

Statin and SGLT2i

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Disease1 trial

References

Drug Info

Quick Facts

Related News